SGNT: Sagent Pharmaceuticals Market Currents - On the Move

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Friday, June 7, 3:24 PM Sagent Pharmaceuticals (SGNT +0.7%) says it's initiated a voluntary nationwide recall of three lots of Vecuronium Bromide for Injection due to the discovery of an elevated impurity detected during routine quality testing of stability samples. The elevated impurity has the potential to result in prolonged neuromuscular blockade for critically ill patients with renal failure. The company said it is not aware of any adverse patient events resulting from the use of this product and will continue its investigation. Comment! [Healthcare, On the Move]
Monday, May 6, 2:47 PM Sagent Pharmaceuticals (SGNT -0.2%) gives back an early 9% lead to trade back into the red today following an earlier Q1 earnings beat and the announcement that it's acuired the remaining 50% interest in its China joint venture Kanghong Sagent Pharmaceutical for $25M. The company also says it expects FY13 net revenue to be around $220M to $250M, and net income to be between $5M and $15M. Street estimates are for the company to report revenue of $238M and net income of $2.4M. Comment! [Healthcare, Earnings, On the Move]
Friday, August 10, 2012, 2:41 PM Wall Street firms are responding today to Sagent Pharmaceuticals' (SGNT -2.6%) revised outlook yesterday, which took the shares down over 25% during the trading session. RBC cut the shares to Sector Perform on the news, citing a lack of earnings visibility over the near term, while Needham, cut its price target to $20 from $25, saying the company "remains its own worst enemy" when it comes to managing estimates and maintaining management's credibility. Comment! [Healthcare, On the Move]
Wednesday, August 31, 2011, 4:26 PM Sagent Pharmaceuticals (SGNT) receives FDA approval for its Orphenadrine Citrate Injection, USP, a skeletal muscle relaxant. Shares +0.1% AH. Comment! [Healthcare, On the Move]
Friday, August 19, 2011, 4:32 PM Sagent Pharmaceuticals (SGNT +4%) closed higher today after announcing the launch of its neuromuscular blocking agent vecuronium bromide - which is currently in short supply in the U.S. - for injection in 10 and 20 mg single-use vials. Comment! [Healthcare, On the Move]
Thursday, June 23, 2011, 10:57 AM Needham downgrades Sagent Pharmaceuticals (SGNT -6.15%) on valuation, saying it's already reached the 12-month price target set when it initiated coverage three weeks ago. The stock is up 62% since its April IPO. Comment! [Healthcare, On the Move]
Wednesday, April 20, 2011, 9:55 AM Today's IPO pricings (actual vs. range): Mission NewEnergy (MNEL) $9 vs. $10-12, 2.8M shares. Sagent Pharma (SGNT) $16 vs. $14-16, 5.8M shares. Tesoro Logistics (TLLP) $21 vs. $19-21, 13M shares (currently +11% to $23.30). Comment! [On the Move]

SGNT Sagent Pharmaceuticals

SGNT

Sagent Pharmaceuticals